Pritelivir healed all HSV lesions by day 28 in 63% of immunocompromised adults vs 34% with comparators.
News|Articles|March 31, 2026
Top FDA news in women's health you missed in Q1 2026
Author(s)Joshua Fitch, Senior Editor
Fact checked by: Benjamin P. Saylor
Take a look back at some of the top FDA-related news items—from de Novo clearances to advancing trials—that Contemporary OB/GYN covered in the first quarter of 2026.
Advertisement
Advertisement
The first quarter of 2026 is all but in the books, with several noteworthy updates from the United States FDA having taken place. From federal agency feedback on testosterone therapy to updated labels for multiple menopausal hormone therapies, there was a lot to keep track of in women’s health in Q1.
Related to this article
A recap of the top videos and podcasts from Contemporary OB/GYN in September 2026, featuring expert interviews on salpingectomy, testosterone evidence, and more.
A recap of the top headlines from Contemporary OB/GYN in September 2026, spanning ACOG's respiratory vaccine guidance to the launch of the Missed & Dismissed podcast.
A recap of Contemporary OB/GYN's top FDA and regulatory news from September 2026.
The FDA accepted an sNDA and granted priority review for elinzanetant to treat VMS in women receiving endocrine therapy to treat or prevent HR+ breast cancer.
Anita Nelson, MD, discusses the FDA's approval extending etonogestrel implant use to 5 years and the new REMS certification clinicians must complete by February 23, 2027.
Experts discuss common patient concerns about vaccination in pregnancy and strategies to improve uptake.
ACOG issued its most comprehensive menopause guidance, grading treatments for VMS, sleep, and mood symptoms.
Advertisement
Advertisement